Keyword: Auris Medical

The EMA has mapped out a path to approval for Auris’ acute hearing loss treatment after the drug failed in phase 3 late last year.

Keyzilen failed to improve scores on the tinnitus scale in the overall study population or the subgroup of patients with otitis media.

Auris Medical has been hit hard by the phase 3 failure of its sudden deafness candidate, leading it to halt work on a second late-stage test.

The stock exchange has given Auris until Oct. 2 to meet the stockholders’ equity requirement.

In our EuroBiotech roundup this week, Actelion reveals financial details of spinout, Novo A/S invests in Evotec and BIAL offloads Parkinson’s drug rights.

Small cap Auris Medical says it will be moving the goalposts on its late-stage test for its tinnitus candidate Keyzilen (AM-101).

Small cap Auris Medical Holding has missed its co-primary endpoints in a key Phase III trial after it failed to beat placebo in treating patients with tinnitus.